
# DaVita Healthcare Partners, Inc

Eduardo Delgadillo Alfaro, Tony Lim, Amy Shekarchi, Neville Tarapore, Eshane Wang





1.7M Patients

70,800+
DaVita Teammates


10 Countries



### **Background**

- Two major divisions
  - DaVita Kidney Care
  - DaVita Medical Group

- U.S. network:
  - 2,510 outpatient dialysis centers
  - Approximately 900 hospitals with acute inpatient dialysis services







**80** Patients

18 Machines/Seats

17
Team Members

**|** Medical Director \$4M Revenue



# **Revenues & Acquisitions**

### Consolidated Statements of Income


(dollars in thousands, except per share data)

Year ended December 31,		
2017	2016	2015
	\$ 9,727,360 (431,308)	
	9,296,052 1,411,415	8,742,542 1,239,703
10,876,634	10,707,467	9,982,245
	\$ 10,093,670 (485,398) 9,608,272 1,268,362	2017     2016       \$ 10,093,670 (485,398)     \$ 9,727,360 (431,308)       9,608,272 (1,268,362)     9,296,052 (1,411,415)

	Year ended December 31,		
	2017	2016	2015
Cash flows from investing activities:	S 18		274
Acquisitions	(803,879)	(563,856)	(96,469)




# Dialysis Revenue by Modality






# Payor Mix






### Private vs. Government






### **Financial Trends**




**Annual Values** 




#### DVA - ROA - Return on Assets


**Annual Values** 





## **Strength of Balance Sheet**







### Fresenius Medical Care





### DaVita vs. Fresenius Stock Prices






# **Operating Margin Comparison**

#### **DaVita**

**DVA - Operating Margin** 


**Annual Values** 



#### Fresenius

FMS - Operating Margin

**Annual Values** 






## **Return on Assets Comparison**

#### DaVita

DVA - ROA - Return on Assets


**Annual Values** 



#### Fresenius

FMS - ROA - Return on Assets

**Annual Values** 





### **Current Challenges**

- Complex federal and state health regulations and laws
- Medicare and Medicaid payment rules and regulations
- Disruptions in federal government
  - Individual mandate (ACA)





### **History of Fraud**

2012

\$495M

• Atlanta whistleblower case settlement

2014

\$389M

Kickback incentives to doctors settlement

2018

\$38.5M

Colorado wrongful death lawsuits

\$270M

• Medicare coding fraud



## Impacts of Changing Payment Reform

#### 2010

#### Affordable Care Act

- Insurance Exchanges
- Tax provisions for insurers
- Broader regulatory requirements
- FFS to P4P

#### 2011

#### **Budget Control Act**

• Reduce Medicare payments yearly through 2027

#### 2017

#### **ESRD Prospective Payment System**

• 2% bundled payment reduction based on quality measures

#### 2018


#### Prop 8 (CA)

Profit cap



### **Future Directions and Innovations**

- Growing international presence
- Care coordination projects
- Private insurer and pharmaceutical partnerships
  - Highmark in 2018, Amgen in 2017
- Risk management and treatment software





### We would recommend investing in DaVita because:

- 1. Good and consistent operating margin
- 2. Historically high ROA
- Low debt/equity ratio
- 4. Dialysis treatment is a life-saving and a growing service
- 5. Expanding global presence

